https://sputnikglobe.com/20230808/cdc-new-covid-19-omicron-subvariant-eris-spreading-rapidly-in-us-1112470385.html
CDC: New COVID-19 Omicron Subvariant ‘Eris’ Spreading Rapidly in US
CDC: New COVID-19 Omicron Subvariant ‘Eris’ Spreading Rapidly in US
Sputnik International
According to health authorities in the US and UK, a new subvariant of COVID-19 Omicron known as EG.5, or colloquially as “Eris,” has become the dominant strain in both countries.
2023-08-08T20:12+0000
2023-08-08T20:12+0000
2023-08-08T20:12+0000
americas
us centers for disease control (cdc)
covid-19
omicron strain
vaccines
us
https://cdn1.img.sputnikglobe.com/img/07e6/02/01/1092663906_0:78:1500:922_1920x0_80_0_0_fd293605e0948c2df75e162c75608c60.jpg
The latest data from the US Centers for Disease Control and Prevention (CDC) on August 5 showed that EG.5 is responsible for between 14-21% of new COVID-19 cases in the US. While that’s not a majority, it’s the largest among a slew of other Omicron subvariants, including the XBB.1.5 subvariant that dominated the US outbreak in the spring of 2023.The WHO hasn’t given EG.5 an official name yet, either, but online users following an informal nomenclature have dubbed it “Eris,” named after the Greek goddess of strife and discord.The Omicron variant and its many offspring have dominated the COVID-19 outbreak globally for nearly two years thanks to their ability to evade immune system defenses and reinfect people who’ve suffered prior infections or been vaccinated.One virologist and researcher, Stuart Turville of the University of New South Wales in Australia, told the media EG.5 was “a little bit more slippery” and “competitive” than other Omicron subvariants and able to “navigate better the presence of antibodies” produced by vaccines or prior infections.Pfizer, Moderna and Novavax are all preparing vaccine boosters that specifically target the XBB-series of Omicron subvariants, in accordance with a June directive by the US Food and Drug Administration (FDA). According to experts, EG.5 shares enough common characteristics with the XBB-series subvariants that the vaccines should be effective against it as well.The FDA hasn’t yet approved any of the boosters, so it’s unclear when they’ll roll out, but health experts are advising Americans to receive them alongside influenza shots and respiratory syncytial virus (RSV), two other highly contagious respiratory infections expected to make a comeback during the colder months.However, the Biden administration has backed off nearly all social restrictions aimed at preventing the spread of COVID-19 or related viruses, including masking requirements in public settings, and an increasing number of employers are moving to end remote working and requiring workers to return to their offices.
https://sputnikglobe.com/20230801/congress-on-covid-origins-ukrainian-drone-attacks-pakistan-bombing-1112309098.html
americas
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2023
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
omicron subvariant; eris; covid-19
omicron subvariant; eris; covid-19
CDC: New COVID-19 Omicron Subvariant ‘Eris’ Spreading Rapidly in US
According to health authorities in the US and UK, a new subvariant of COVID-19 Omicron known as EG.5, or colloquially as “Eris,” has become the dominant strain in both countries.
The latest data from the US Centers for Disease Control and Prevention (CDC)
on August 5 showed that EG.5 is responsible for between 14-21% of new COVID-19 cases in the US. While that’s not a majority, it’s the largest among a slew of other Omicron subvariants, including the XBB.1.5 subvariant that dominated the US outbreak in the spring of 2023.
The subvariant has been designated a variant under monitoring by the World Health Organization (WHO), but not yet marked as a variant of interest or of concern.
The WHO hasn’t given EG.5 an official name yet, either, but online users following an informal nomenclature have dubbed it “Eris,” named after the Greek goddess of strife and discord.
The Omicron variant and
its many offspring have dominated the COVID-19 outbreak globally for nearly two years thanks to their ability to evade immune system defenses and reinfect people who’ve suffered prior infections or been vaccinated.
One virologist and researcher, Stuart Turville of the University of New South Wales in Australia, told the media EG.5 was “a little bit more slippery” and “competitive” than other Omicron subvariants and able to “navigate better the presence of antibodies” produced by vaccines or prior infections.
Andrea Garcia, the American Medical Association’s vice president for science, medicine and public health, told US media last month that EG.5 doesn’t seem to cause any worse infection than prior Omicron subvariants and may be more susceptible to newer COVID-19 vaccines, including those expected to be rolled out by pharmaceutical companies in the coming months.
Pfizer, Moderna and Novavax are all preparing vaccine boosters that specifically target the XBB-series of Omicron subvariants, in accordance with a June directive by the US Food and Drug Administration (FDA). According to experts, EG.5 shares enough common characteristics with the XBB-series subvariants that the vaccines should be effective against it as well.
The FDA hasn’t yet approved any of the boosters, so it’s unclear when they’ll roll out, but health experts are advising Americans to receive them alongside influenza shots and respiratory syncytial virus (RSV), two other highly contagious respiratory infections expected to make a comeback during the colder months.
However, the Biden administration has backed off nearly all social restrictions aimed at preventing the spread of COVID-19 or related viruses, including masking requirements in public settings, and an increasing number of employers are moving to end remote working and requiring workers to return to their offices.
